Navigation Links
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced encouraging results in an ongoing Dana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. To date, 10 patients were evaluable for best overall tumor response (assessed at least after 8 weeks / 2 chemotherapy cycles), whereby all 10 women had previously failed three lines of chemotherapy (starting fourth line). 1 patient had a partial response, 5 stable disease and 4 progressive disease. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

The primary objective of this open-label single-arm Phase 2 is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women may be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. A link to the trial description and contact information is available at www.novelos.com under 'Clinical Trials' section.

"I am encouraged by these preliminary results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients," said Dr. Carolyn Krasner, the Principal Investigator. "Most women, having failed three lines of chemotherapy, would be expected to progress in about eight weeks."

"We look forward to continuing to work closely with Dana-Farber/Partners on developing NOV-002 for this indication," said Harry Palmin, President and CEO of Novelos. "Meanwhile, Novelos remains on-track for full enrollment of our pivotal Phase 3 trial of NOV-002 for lung cancer in the first quarter 2008."

Acco
'"/>




Page: 1 2 3

Related medicine technology :

1. Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... , June 18, 2013  In a letter to ... , M.D., of Lake View, Iowa , ... receive annual influenza vaccine is neither scientifically justified nor ethically ... article in the summer issue of the Journal ... official statistics are correct, and an average of 36,000 patients ...
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... 18, 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced that it has ... clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety ... of cenderitide in patients with chronic heart failure. ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... demonstrated in an IRB approved, randomized, placebo controlled, double-blinded ... has an impact on allergic rhinitis, a clinical condition ...
Cached Medicine Technology:Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 2Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 3Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 4Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 2Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 3
(Date:6/19/2013)... 19, 2013 Indosoft Inc., developers ... for Asterisk, announced today the availability of ... enhancement offers improved options for extracting, consolidating and ... effective contact center management. , Large Asterisk based ... as it happens from the call center software. ...
(Date:6/19/2013)... BEACH, Florida (PRWEB) June 19, 2013 ... an emphasis upon crystal meth addiction treatment, helping men ... this powerful drug. , Crystal meth is a stimulant ... manufactured. The drug is most commonly smoked, but it ... It is commonly created in homemade labs using common ...
(Date:6/19/2013)... June 19, 2013 CoachingWebsites, ... for coaches, announced today its affiliation with ... will offer exclusive websites and marketing solutions and ... “This new partnership with Active Intelligence shows our ... to its fullest,” says Greer Van Dyck, Online ...
(Date:6/19/2013)... The US Drug Watchdog says, ... specifically designed to help a recipient of a DePuy Pinnacle ... elevated levels of cobalt, and chromium, because we believe this ... device is doing. In the event the cobalt, or chromium ... the person will need to consider, including possible revision surgery ...
(Date:6/19/2013)... 19, 2013 The Mesothelioma Victims ... Control of the 2500 to 3000 citizens, who will ... mesothelioma this year, about one third will be US ... diagnosed with this asbestos exposure form of cancer, or ... access to the nations most skilled mesothelioma compensation settlement ...
Breaking Medicine News(10 mins):Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3
... the leading cause of visual impairment and blindness in ... people. ,The American Academy of Ophthalmology ... there are new treatments that can usually recover lost ... ,The Academy encourages those older than 50 ...
... men who become impotent after prostate cancer surgery may find ... the penis,// which assists in restoring the lost erectile function, ... findings came to light after a study of nearly 44 ... erectile function, following its loss after treatment for prostate cancer. ...
... caused by meningococcal infection and the disease spreads like wild ... of weeks in the late 1990s. Mortality rate in cases ... Patients also run a high risk of serious disability after ... each year 170,000 people around the world die of this ...
... breakfast was recalled from Singapore's markets as a precautionary ... that the product might be contaminated and cause botulism, ... were told to recall Earth's Best Organic 2 Apple ... from the Agri-Food and Veterinary Authority. ,The ...
... to a recent study published in February 21 Journal ... cancer// are at a higher risk of developing a ... for childhood cancer have resulted in a current overall ... shown that these survivors are specifically at a higher ...
... distress should be evaluated for primary ciliary dyskinesia, a ... fibrosis. ,According to Thomas Ferkol, M.D., ... that about 80 percent of patients with primary ciliary ... ,"The diagnosis of PCD requires a high ...
Cached Medicine News:Health News:Spring is Time for Age-Related Macular Degeneration (AMD) Awareness 2Health News:Survivors of Childhood Cancers at Higher Risk for Secondary Cancer 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: